new post
StocksRunner logo
mail
search
 
menu
 
Cytokinetics Incorpo
$65.60
+4.59%
 
  Set Alerts  
  
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 

CYTK Stock Analysis & IQ Rating | Cytokinetics Incorpo

 
 
 

CYTK

 

Cytokinetics Incorpo

$65.60

 
+$2.88 | +4.59%
 
  Set Alerts  
  
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 
 
52W High
$70.98
 
 
MKT CAP
$8.02B
 
52W Low
$29.31
 
 
VOL
$6.48M
 
P/E Ratio
N/A
 
 
AVG VOL
$1.86M
 
RSI
56.83
 
 
TREND
Uptrend
 
 
 

CYTK Stock IQ

 
lock  Login to see Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 

CYTK Target Price

 
 
 

Strengths

 
 

CYTK Rewards

 Upgraded on attractively valued

CYTK Rewards

 Earnings are forecast to grow

 
 

CYTK Price Performance

 
 

$67.21   (-2.40%)

$50.4   (+30.16%)

$38.09   (+72.22%)

$48.51   (+35.23%)

 
 
1year
6month
3month
1month
 

CYTK Risk Level

 
 

CYTK has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

 
 
 
CYTK Risk Level
Low
LOW
HIGH
 

CYTK Analysts Opinion

 

CYTK overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

 
 
 

Earnings

×
 

Earnings

 
 
 

Rating

×
 

Rating

 

CYTK Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

 

CYTK Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

 
 

Future

×
 

Future

 

CYTK Future Sentiment

 Earnings are forecast to grow

 
 

CYTK Analysts Opinion

CYTK Analysts opinion is positive and also has improved from the past 3 months

 

CYTK Street Sentiment

 

Analysts perspectives on the stock desirability, trend direction and growth potential

 
 
89%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
100%
67%
100%
 

CYTK Street Sentiment 

CYTK Street Sentiment is extremely bullish and have positive views on the near-term outlook

 

CYTK Performance Sentiment

 
Sentiments overview associated with CYTK events and the stock performance.
 
 
89%
11%
Positive
Negative
24 out of 27
events present
3 out of 27
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 

Technical Price Levels

 

Average key support and resistance price levels

 
 
Support
Price
 
$62.72
 
Resistance
Price
 
$59.82
 
 
Current Price Range
 
$68.15
 
 
Show methods +
 
 
Linked to CYTK
IQ
Close Price
Change
 

NVO

3.74

48.10

+0.07%

 

AZN

4.28

91.55

+0.22%

 
 
 
CYTK Latest Analysis +
 
 
FAQ About CYTK Stock Insights
 

What is CYTK current stock price?

What are CYTK stock strengths?

What is CYTK Risk Level?

What is CYTK market cap and volume?

What is CYTK current Stock IQ?

Should I buy CYTK stock right now?

Is CYTK a Strong Buy right now?

What does a 'Strong Buy' rating mean for CYTK?

What does a 'Strong Sell' rating mean for CYTK?

What factors influence CYTK's Stock IQ?

 
 
StocksRunner

Explore our CYTK Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored CYTK Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our CYTK Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner Overview
 
StocksRunner Trending
 
StocksRunner Screener
 
StocksRunner Insights
 
StocksRunner Top Rated
 
StocksRunner Momentum
 
StocksRunner Leaders
mail
 
 
 

CYTK

 

Cytokinetics Incorpo

 
 

Current Price

 

$65.60

 
+$2.88 | +4.59%
 
 
52W High
$70.98
 
 
MKT CAP
$8.02B
 
52W Low
$29.31
 
 
VOL
$6.48M
 
P/E Ratio
N/A
 
 
AVG VOL
$1.86M
 
RSI
56.83
 
 
TREND
Uptrend
 
 
 
Set Alerts
  
  Overview  
  
  Comments  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
 
 
 
 

Target Price

 
 
 
 
Not Enough Information
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 
 

CYTK Rewards

 Upgraded on attractively valued

CYTK Rewards

 Earnings are forecast to grow

 
 
 

Linked to CYTK

 
 
 
Symbol
IQ
Close
Change
 

NVO

3.74

48.10

+0.07%

 

AZN

4.28

91.55

+0.22%

 
 
 
 
 
user
 
 
 
 

CYTK Price Performance

 
 

$67.21   (-2.40%)

$50.4   (+30.16%)

$38.09   (+72.22%)

$48.51   (+35.23%)

 
 
1year
6month
3month
1month
 

CYTK Analysts Opinion

 

CYTK Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

 
 
 

Earnings

×
 

Earnings

 
 
 

Rating

×
 

Rating

 

CYTK Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

 

CYTK Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

 
 

Future

×
 

Future

 

CYTK Future Sentiment

 Earnings are forecast to grow

 
 

CYTK Analysts Opinion

CYTK Analysts opinion is positive and also has improved from the past 3 months

 

CYTK Street Sentiment

 

Analysts perspectives on the stock desirability, trend direction and growth potential

 
 
89%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
100%
67%
100%
 

CYTK Street Sentiment 

CYTK Street Sentiment is extremely bullish and have positive views on the near-term outlook

 

CYTK Risk Level

 
 

CYTK has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

 
 
 
CYTK Risk Level
Low
LOW
HIGH
 
CYTK Performance Sentiment
 
Sentiments overview associated with CYTK events and the stock performance.
 
 
89%
11%
Positive
Negative
24 out of 27
events present
3 out of 27
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

Technical Price Levels

 

Average key support and resistance price levels

 
 
Support
Price
 
$62.72
 
Resistance
Price
 
$59.82
 
 
Current Price Range
 
$68.15
 
 
Show methods +
 
 
 
 
 
 

CYTK Stock IQ

 
 
 
lock  Login to unlock Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 
 

CYTK Latest Analysis

 
 
 

HC Wainwright & Co. Maintains Cytokinetics (CYTK) Buy Recommendation. Fintel reports that on December 22 2025 HC Wainwright &. Co. maintained coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 33.06% Upside

 

Today

$65.60 | +4.59%
 
Rating

Needham Maintains Cytokinetics (CYTK) Buy Recommendation. Fintel reports that on December 22 2025 Needham maintained coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 33.06% Upside

 

Today

$65.60 | +4.59%
 
Rating

Cytokinetics Wins FDA Approval for Cardiovascular Drug Stock up . CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech opening a long-term growth runway in cardiology.

 

Today

$65.60 | +4.59%
 
Activity
Momentum
Potential

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo. On Friday the United States Food and Drug Administration (FDA) approved ) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional .Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM myosin inhibition with Myqorzo reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.The full United States Prescribing Information fo

 

Today

$65.60 | +4.59%
 
Activity
Activity
Potential

Cytokinetics Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript.

 

Today

$65.60 | +4.59%
 
Activity

Cytokinetics Wins FDA Approval For Its First Drug Taking On Bristol Myers. Cytokinetics won its first Food and Drug Administration approval late Friday leading shares to jump in after-hours action.The post Cytokinetics Wins FDA Approval For Its First Drug Taking On Bristol Myers appeared first on Investor'.s Business Daily.

 

Fri Dec 19, 2025

$62.72 | +0.84%
 
Activity
Momentum

Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy.

 

Fri Dec 19, 2025

$62.72 | +0.84%
 
Activity

This Cytokinetics Director Sold 5000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?.

 

Fri Dec 19, 2025

$62.72 | +0.84%
 
Activity
Momentum

Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms. Cytokinetics is on the cusp of its first FDA approval analysts say leading up to the agencys decision date for the drug called aficamten.The post Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms appeared first on Investor'.s Business Daily.

 

Fri Dec 19, 2025

$62.72 | +0.84%
 
Activity

Cytokinetics Wins China Approval For Myqorzo In Obstructive Hypertrophic Cardiomyopathy . (RTTNews) - Cytokinetics Incorporated (CYTK) said on Wednesday that Chinas National Medical Products Administration has approved Myqorzo for the treatment of adults with obstructive hypertrophic cardiomyopathy.

 

Wed Dec 17, 2025

$59.82 | -3.55%
 
Activity
 
 
 
 
 
StocksRunner

Discover CYTK Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CYTK. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our CYTK Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CYTK Stock trends

CYTK Stock performance

CYTK Stock analysis

CYTK investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

CYTK Alerts

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental Indicator (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 
 
Cancel
 
×
 
0/666
joker
 
Post
 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing CYTK

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing CYTK

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.